Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 4Genitourinary 3Breast 3Other hematologic neoplasm 2Thoracic 1Sarcoma 1Plasma cell 1Myeloid 1Lymphoid 1Head & Neck 1CNS 1

Conditions

Breast Neoplasms 3Cardiotoxicity 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 347Paclitaxel 309Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 214Letrozole 185Fulvestrant 176Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 112pembrolizumab 112Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 65Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Reverse Transcriptase Polymerase Chain Reaction × Breast × Clear all
NCT00499083 2023-09-29

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

University of Nebraska

Phase 2 Completed
17 enrolled 5 charts
Breast

Breast Neoplasms

NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

University of Nebraska

Phase 2 Terminated
3 enrolled 6 charts
Breast

Breast Neoplasms

NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡